Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl
Topics & Concepts
MedicineUstekinumabPsoriasisPlaceboPsoriasis Area and Severity IndexClinical endpointInternal medicineAdverse effectClinical trialRandomizationDosingBody surface areaPlaque psoriasisRandomized controlled trialDermatologyAdalimumabDiseasePathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases